Document is current
Any future updates will be listed below
-
Authors
Wang, Yilong
Wang, Anxin
Li, Hongwei
Li, Zhanquan
Hu, Bo
Li, Xiaogang
Zheng, Huaguang
Fu, Lu
Hu, Hongtao
Nie, Zhiyu
Qin, Yulin
Zhao, Bilian
Wei, Di
Karlson, Björn W.
Bots, Michiel L.
Chen, Yundai
Wang, Yongjun
-
Funding
Funding for this research was provided by:
Astrazeneca (NA)
- License Information
-
More Information
Article History
Received: 12 March 2020
Accepted: 16 September 2020
First Online: 11 November 2020
Ethics approval and consent to participate
: The study protocol has been approved by the ethics committees at the study sites.Written consent was obtained from every participant prior to any study-specific procedures.
: This study will be published in scientific journals and be presented at conferences to target a wide range of audiences.
: Yulin Qin, Bilian Zhao, Di Wei, and Björn W. Karlson are employees of AstraZeneca. Michiel L. Bots is indirectly supported by a grant from AstraZeneca for his contribution to the METEOR-China trial. Yilong Wang, Anxin Wang, Hongwei Li, Zhanquan Li, Bo Hu, Xiaogang Li, Huaguang Zheng, Lu Fu, Hongtao Hu, Zhiyu Nie, Yundai Chen, and Yongjun Wang have no competing interests to declare.
